Pharmacogenetic implications in the management of metabolic diseases in Brazilian populations by Hirata, Rosario Dominguez Crespo et al.
Braz. J. Pharm. Sci. 2018;54(Special):e01005 1
Brazilian Journal of 
Pharmaceutical Sciences
http://dx.doi.org/10.1590/s2175-97902018000001005
R
ev
ie
w
*Correspondence: R. D. C. Hirata. Departmento de Análises Clínicas e Toxi-
cológicas, Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. 
Av. Prof. Lineu Prestes, 580 B-17 - 05508-900 São Paulo, SP, Brazil. Tel.: 
+55-11-30913660. E-mail: rosariohirata@usp.br
Pharmacogenetic implications in the management of metabolic 
diseases in Brazilian populations
Rosario Dominguez Crespo Hirata1, Alvaro Cerda2, Fabiana Dalla Vecchia Genvigir1, Mario 
Hiroyuki Hirata1*
1Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo, 
SP, Brazil, 2Center of Excellence in Translational Medicine, CEMT-BIOREN, Departamento de Ciencias Básicas,  
Universidad de La Frontera, Temuco, Chile
Dyslipidemia, diabetes, obesity and hypertension are common metabolic diseases. In the last decades, 
unhealthy lifestyle and aging have leads to an increased incidence of these diseases, increasing 
morbidity and mortality by cardiovascular causes. The treatment of metabolic diseases includes life-
style interventions as healthy diet and physical exercise, as well as pharmacological interventions. 
Several drugs are available for the management of metabolic diseases including among others lipid-
lowering antidiabetics and antihypertensive drugs. Variability in response to these drugs is influenced 
by both genetic and non-genetic factors. Polymorphisms in genes related to drug pharmacokinetics and 
pharmacodynamics have been shown to influence drug efficacy and safety. This review is focused on 
pharmacogenetic studies related to the management of metabolic diseases in samples of the Brazilian 
population. Associations of variants in drug metabolizing enzymes and transporters, drug target and 
metabolism-related genes with the efficacy and safety of lipid-lowering, antidiabetic and antihypertensive 
drugs are described. Most pharmacogenetic studies in Brazil have focused in pharmacological response 
to a small group of drugs, as statins and some antihypertensives, while there are almost no studies on 
antidiabetic and antiobesity drugs. Some studies reported significant associations of gene polymorphisms 
with drug response confirming previous data from other populations, whereas other works did not 
replicate, which may relay on the genetic admixture of our population. In conclusion, further studies are 
necessary considering larger sample sizes, new unexplored drugs and more genetic variants to obtain 
stronger conclusions to explore clinical applications of pharmacogenetic studies in our population.
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INTRODUCTION
Metabolic diseases are interrelated disorders that 
contribute to the development of cardiovascular disease, 
which have experienced a notable increase in their rates 
in the last decades due to several contributing factors 
as ageing and mainly those related to life-style changes 
(unhealthy dietary pattern, physical inactivity and 
sedentary lifestyle, smoking, among others) which are 
reflected in high prevalence of obesity, type 2 diabetes 
(T2D) and, lately, metabolic syndrome (MetS) worldwide; 
including Brazil with a prevalence of MetS of almost 30% 
(De Carvalho Vidigal et al., 2013). 
The origin of metabolic disorders can be explained 
by a number of conditions that lead to a proinflammatory 
status, such as over nutrition/obesity, insulin resistance, 
dyslipidemia and hypertension. Among them, obesity is 
a well-known risk factor conducting to atherosclerosis by 
increasing glucose levels, blood pressure and impairing 
lipid profile. Moreover, the increase of inflammatory 
mediators related to the expansion of adipose tissue and 
the changes observed in adipose tissue in response to over 
nutrition/obesity induce insulin resistance and oxidative 
stress, with the potential to impair several biological 
pathways that contributes to the establishment of insulin 
resistance and further development of atherosclerosis and 
cardiovascular diseases (Yoo, Choi, 2014).
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Changes in life-style are the first line treatment for 
the management of metabolic diseases. Dietary changes 
and physical activity improve metabolic parameters, 
mainly by changing anthropometric measures related to 
body composition as the reduction of fat mass related to 
visceral obesity. Nevertheless, when dietary changes are 
not enough to maintain patients with metabolic diseases at 
a low cardiometabolic risk, pharmacological intervention 
is necessary. 
The pharmacological management of metabolic 
diseases has become a challenge due to the multifactorial 
components of these diseases, in which many times insulin 
resistance/T2D, hypertension and dyslipidemia coexist. 
Moreover, aging of the population and the increasing 
young age at which these alterations occurs result in 
long term exposure to the therapeutical drugs (Gouni-
Berthold, Berthold, 2014). Moreover, it is well known 
that drug response, as effectiveness, safety and adverse 
drug reactions, depends on genetic and non-genetic 
factors, such as environmental/nutritional factors, drug 
interactions and drug metabolism, that could determinate 
the individual response to the therapeutical drugs. 
Several pharmacogenetic studies have been 
performed in different populations around the world, in 
order to elucidate the influence of gene polymorphisms 
on the response to drugs used in the management of 
hyperglycemia, high blood pressure (BP), dyslipidemia 
and other metabolic diseases. In this way, Brazilian 
populations have been proposed as an interesting subject 
to be evaluated due to the difficulty to use an extrapolation 
of pharmacogenetic studies from other populations. The 
extensive miscegenation resulted in a genetic admixture 
from three major ethnical components, Europeans, Africans 
and Amerindians. The complex ancestral component of our 
population has important implications for pharmacogenetic 
studies and their applications (Cerda, Hirata, Hirata, 2014).
This review is focused on the pharmacogenetic studies 
that investigate the influence of gene polymorphisms on 
response to drugs used for treatment of metabolic diseases 
in Brazilian populations.
PHARMACOGENETICS AND DYSLIPIDEMIA
Dyslipidemia
Dyslipidemia is an important risk factor for 
coronary artery disease (CAD) and stroke. Several 
long-term prospective studies have consistently shown 
that characteristic alterations in lipid profile observed 
in dyslipidemia, such as hypercholesterolemia and 
hypertriglyceridemia (isolated or mixed if both are present), 
as well as low levels of high-density lipoprotein (HDL) 
cholesterol, have increased incidence of cardiovascular 
disease (CVD). These alterations in the lipid profile are 
etiologically classified as primary dyslipidemia, when the 
cause is of genetic origin; or secondary, if the alteration in 
the lipid profile is a consequence of inadequate life-style, 
some morbid conditions or as an adverse reaction to drugs 
(Faludi et al., 2017). 
Prevention and a proper and timely management 
of dyslipidemia can markedly reduce morbidity and 
mortality due to cardiovascular causes. The treatment of 
dyslipidemia includes non-pharmacological strategies as a 
first line intervention, being recommended to modify life-
style through nutritional therapy, weight-loss, reduction 
of alcohol intake, physical activity, among others. In high 
cardiovascular risk patients, as well as those patients with 
moderate risk who do not reach the therapeutic goals with 
lifestyle modifications, pharmacological intervention 
should be prescribed (Faludi et al., 2017).
Several drugs are available for the treatment of 
dyslipidemia and the choice of a specific medicine will 
depend on the type of dyslipidemia according to the 
altered parameter in lipid profile. Regarding cholesterol-
lowering, statins are the most common drugs, with an 
important body of evidence supporting their benefits in 
preventing CVD in hypercholesterolemic patients. Also 
the ezetimibe (an inhibitor of cholesterol absorption) 
and resins (bile acid sequestrants) could be used in 
patients with statin intolerance or even could be used 
in association in patients at a high cardiovascular risk. 
Regarding treatment of hypertriglyceridemia, fibrates are 
the first choice, but also niacin and omega-3 fatty acids 
are available pharmacological strategies (Gryn, Hegele, 
2014; Faludi et al., 2017).
Cholesterol-lowering drugs
Statins are the main focus of the pharmacogenomic 
studies on lipid-lowering therapy probably because 
they are very effective to treat hypercholesterolemia 
and to reduce the cardiovascular risk of patients with 
metabolic diseases. Statins also have pleiotropic 
effects that help improve endothelial function, stabilize 
plaques, and decrease inflammation contributing for 
primary and secondary prevention of cardiovascular and 
cerebrovascular diseases. Non-statin drugs, used as mono- 
or combined therapy, are becoming also focus of recent 
pharmacogenetic studies, mainly for patients with severe 
hypercholesterolemia, and/or who experienced lack of 
response or statin-induced muscular events (Gryn, Hegele, 
2014; Alfonsi, Hegele, Gryn, 2016). 
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Statins are cholesterol synthesis inhibitors that 
competitively block 3-hydroxy-3-methylglutaryl-
coenzyme A reductase (HMGCR), the enzyme limiting 
the de novo synthesis of cholesterol in the liver. Statins 
are effective, well-tolerated and safe lipid-lowering 
drugs, but some patients do not respond to treatment and 
others experience adverse events, such as myopathy. 
The variability in the response to statins is attributed 
to genetic and non-genetic factors, such as lifestyle, 
drug interactions, intolerance or lack of adherence to 
pharmacotherapy (Gryn, Hegele, 2014; Patel et al., 2014; 
Alfonsi, Hegele, Gryn, 2016).
Pharmacogenetic studies of statins have focused 
mainly on genes in pharmacokinetic and pharmacodynamic 
pathways, as well as genes involved in lipid metabolism. 
Polymorphisms in these genes have been associated 
mainly with variability in statins efficacy and safety and 
with risk for cardiovascular events (Patel et al., 2014; 
Alfonsi, Hegele, Gryn, 2016; Leusink et al., 2016; Ruaño 
et al., 2016). 
Pharmacokinetics-related genes
Several studies have reported that polymorphisms 
in genes encoding drug metabolizing enzymes influence 
the liver metabolism of specific statins and can cause a 
relevant effect on therapeutic response and the risk of 
adverse effects (Gelissen, McLachlan, 2014). Results from 
studies in Brazilian sample populations that investigated 
the influence of pharmacokinetics-related genes on 
response to statins are summarized in Table I.
Drug metabolizing enzymes and transporters
Cytochrome p450 (CYP) enzymes, such as CYP3A4 
and CYP3A5, are involved in the metabolism of several 
classes of drugs including statins. Polymorphisms 
in CYP3A4 and CYP3A5 genes have been shown to 
influence the response to statins, including resistance 
to pharmacotherapy in other populations (Gelissen, 
McLachlan, 2014; Alfonsi, Hegele, Gryn, 2016). 
Two studies investigated CYP3A4 polymorphisms 
in Brazilian subjects with hypercholesterolemia. 
CYP3A4*1B (g.-392A>G), CYP3A4*22 (g.15389C>T) 
alleles were not associated with cholesterol-lowering 
response and risk for adverse drug reactions (ADR) after 
long term treatment with simvastatin (Fiegenbaum et al., 
2005a). Similarly, our group reported that CYP3A4*1B 
did not influenced the serum lipids reduction after short 
term treatment with atorvastatin (Wilrrich et al., 2013). 
CYP3A5 polymorphisms were also evaluated in 
Brazilian samples. The CYP3A5*3C and *1D alleles did 
not influence the response to simvastatin (Fiegenbaum 
et al., 2005a) and atorvastatin (Willrich et al., 2013). 
Interestingly, our group observed that carriers of the 
haplotype CYP3A5*3A, a combination of *3C and *1D 
alleles, showed reduced efficacy of atorvastatin compared 
to non-carriers (Willrich et al., 2008). Moreover, the 
CYP3A5 AGT haplotype, which includes the *3C 
allele, was associated with lower basal CYP3A5 mRNA 
expression in peripheral blood mononuclear cells (Willrich 
et al., 2013). 
Adenosine triphosphate (ATP)-binding cassette 
(ABC) transporters are a family of efflux transporters that 
are involved in the bioavailability of several drugs and 
some statins. The most commonly studied is the ABCB1, 
also known as P-glycoprotein (P-gp) and multidrug-
resistant protein 1 (MDR1). Polymorphisms in the ABCB1 
were shown to influence the cholesterol-lowering response 
to statins and the risk for statin-related muscular adverse 
events, such as myalgia in several studies (Gelissen, 
McLachlan, 2014; Gryn, Hegele, 2014; Patel et al., 2015; 
Alfonsi, Hegele, Gryn, 2016).
Three  var ian t s  o f  the  ABCB1  (1236C>T, 
c.2677G>T/A and c.3435C>T) were studied in Brazilian 
hypercholesterolemic (HC) subjects treated with 
simvastatin and atorvastatin. Fiegenbaum et al. reported 
that carriers of c.1236T and c.2677non-G alleles had 
increased response to simvastatin long-term treatment. 
Moreover, three alleles of ABCB1 (c.1236T, c.2677non-G 
and c.3435T) conferred lower risk for statin-induced ADR-
induced (Fiegenbaum et al., 2005a). Our group described 
that HC subjects carrying ABCB1 T/T haplotype have 
high basal serum concentrations of total and low-density 
lipoprotein (LDL) cholesterol but the ABCB1 variants 
did not influence the response to short-term treatment 
with atorvastatin (Rodrigues et al., 2005). In a larger 
sample of HC subjects, we found that c.2677A allele is 
associated with greater LDL cholesterol reduction induced 
by atorvastatin (OR: 5.69, CI95%: 1.28-25.24, p=0.022). 
Interestingly, the c.2677T/A allele was also associated 
with reduction of ABCB1 mRNA in PBMC (Rebecchi et 
al., 2009). 
The variant 2012G>T of the ABCC1, which encodes 
the multidrug resistance-associated protein 1 (MRP1), was 
also investigated by our group. The 2012T allele carriers 
had low basal HDL cholesterol levels, but this variant did 
not influence the response to atorvastatin (Rebecchi et 
al., 2009). 
Uptake transporters, such as the organic anion 
transporter polypeptides (OATP), play also an important 
role in the efficacy and safety of statins. Polymorphisms 
in the SLCO1B1, which encodes the organic anion-
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transporting polypeptide 1B1 (OATP1B1), are important 
predictors of the clinical response to statins, mainly the risk 
for statin-related muscular events (Gelissen, McLachlan, 
2014; Gryn, Hegele, 2014; Patel et al., 2015; Alfonsi, 
Hegele, Gryn, 2016; Leusink et al., 2016). Based on the 
clinical evidence of simvastatin-induced myopathy, the 
Clinical Pharmacogenetics Implementation Consortium 
(CPIC) guidelines recommend dose adjustments in carriers 
of the SLCO1B1 rs4149056 C allele (c.521T>C) (Ramsey 
et al., 2014).
The SLCO1B1 c.388A>G, c.463C>A and c.521T>C 
variants were studied in Brazilian HC subjects. Our research 
group reported that SLCO1B1 c.388GG genotype carriers 
are more likely to have greater LDL cholesterol response 
to atorvastatin (OR: 3.2, CI95%: 1.3-8.0, p=0.012) but 
the c.463C>A and c.521T>C variants did not influence 
the atorvastatin response (Rodrigues et al., 2011). Similar 
results were described by Sortica et al, with the SLCO1B1 
c.388G allele associated with greater reduction of total and 
LDL cholesterol after long term treatment with simvastatin 
(Sortica et al., 2012). SLCO1B1 c.388A>G and c.521T>C 
variants were also investigated in a sample of heterozygous 
Familial Hypercholesterolemic (FH) subjects treated with 
atorvastatin (20-80 mg/day) and ezetimibe (10mg/day) for 
12 months. SLCO1B1 polymorphisms and haplotypes were 
not associated with ADR induced by cholesterol-lowering 
drugs (Santos et al., 2012).
The variant c.-71T>C of the SLCO2B1, which 
encodes the membrane transporter OATP2B1, was also 
studied by our group, but no association was found 
with the lipid response to atorvastatin (Rodrigues et al., 
2011).
Pregnane X receptor  (PXR),  const i tu t ive 
androsterone receptor (CAR), peroxisome proliferator-
activated receptor alpha (PPAR-alpha) and other 
nuclear receptors regulate the expression of major drug 
metabolizing enzymes and transporters upon induction by 
xenobiotics and pharmacological drugs. Polymorphisms 
in genes encoding PXR (NR1I2), CAR (NR1I3), PPAR-
alpha (PPARA) and retinoic X receptor alpha (RXR-alpha, 
RXRA) have been suggested to influence variability in 
CYP3A expression and activity and they may influence 
drug response (Klein, Zanger, 2013).
One  s tudy  inves t iga t ed  the  in f luence  o f 
polymorphisms within the NR1I2, NR1I3, PPARA and 
RXRA on simvastatin or atorvastatin response in Brazilian 
HC patients treated during one year. NR1I2 (c.-1663T>C, 
c.-22-7659T>C), NR1I3 (c.540C>T, c.238+1099A>G), 
PPARA (c.484C>G) and RXRA (Indel -/A) did not 
influence lipid-lowering response to these statins. NR1I3 
c.540TT genotype carriers had lower risk for statin-
induced liver or muscle ADR, but the other variants were 
not associated with safety of statins (Lima et al., 2013).
Pharmacodynamics-related genes
Polymorphisms in the HMGCR, which encodes 
the target of statins, and other genes involved in the 
cholesterol homeostasis and lipid metabolism have been 
proposed as predictors of the statin response. Studies that 
investigated the influence of pharmacodynamics-related 
genes on response to statins in Brazilian populations are 
depicted in Table II.
Some variants of the HMGCR were associated with 
the response to statins. HMGCR haplotype H2 and H7 
carriers experienced a 5% to 20% lower reduction of LDL 
cholesterol after treatment with simvastatin. HMGCR 
variants rs17244841 (SNP12) and rs17238540 (SNP29) 
were associated with lower LDL cholesterol reduction in 
response to pravastatin and atorvastatin. The HMGCR 
rs1724481, rs10474433 and rs17671591 polymorphisms 
were also associated with response to various statins 
(Gelissen, McLachlan, 2014; Gryn, Hegele, 2014; Patel 
et al., 2014; Alfonsi, Hegene, Gryn, 2016). 
One study investigated the HMGCR SNP29 in 
Brazilian HC patients taking long term treatment with 
simvastatin or atorvastatin (10-80 mg/day), but no 
association was found with oxidative stress biomarkers, 
such as plasma malondialdehyde, oxidized LDL and total 
antioxidant activity, and plasma tocopherol (Botelho et 
al., 2012). 
LDL receptor mediates the uptake of LDL particles 
in the cell surface by binding to the apolipoprotein B 
(ApoB), the structural protein of the very low-density 
lipoprotein (VLDL) and LDL. Variants in the LDL 
receptor encoding gene, LDLR, were described to be 
associated with increased plasma lipids, reduced response 
to several statins and high risk for cardiovascular events 
(Gelissen, McLachlan, 2014; Gryn, Hegele, 2014; Leusink 
et al., 2016; Postmus et al., 2014; Alfonsi, Hegele, Gryn, 
2016; Ruaño et al., 2016). 
Our group investigated the influence of three variants 
of the LDLR (Val653Val/AvaII, Asn591Asn/HincII and 
g.42716A>G/PvuII) in HC subjects. LDLR AvaII (A+A+) 
and PvuII (P1P1) genotypes were associated with high 
basal total cholesterol, LDL cholesterol and apoB plasma 
concentrations and reduced response of these lipids to 
fluvastatin (Salazar et al., 2000). Further we reported that 
the LDLR c.*52G>A variant, located in the 3´UTR, was 
associated with lower risk of hypercholesterolemia (OR: 
0.58, 95%CI: 0.34-0.99, p=0.043) but not with response 
to atorvastatin (Zambrano et al., 2015).
Pharmacogenetic implications in the management of metabolic diseases in Brazilian populations
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Santos et al investigated the influence of LDLR 
mutations on response to long term (12 months) treatment 
with cholesterol-lowering drugs (atorvastatin associated 
or not with ezetimibe or adjuvant lipid-lowering drugs). 
Carriers of null mutations showed higher reduction of total 
and LDL cholesterol plasma levels after treatment. LDLR 
mutations were associated with greater likelihood of not 
reaching LDL cholesterol target values after treatment 
(OR: 9.07, 95%CI: 1.41-58.16, p=0.002). In addition null 
and defective mutations were not associated with statin-
induced muscle ADR (Santos et al., 2014b).
APOB encodes ApoB, the ligand of LDL particles to 
the LDL receptor in the surface of the cells. Polymorphisms 
in APOB are associated with plasma ApoB and LDL 
cholesterol levels and risk of cardiovascular diseases 
(Benn, 2009). 
The APOB c.7545C>T, c.12451G>A and 5´Indel 
polymorphisms have been studied in Brazilian samples. 
The c.7545C>T variant, also named XbaI, was associated 
with high levels of plasma total and LDL cholesterol 
(Guzman et al., 2000) and with hypercholesterolemia 
(OR: 2.2, 95%CI: 1.48-3.2, p=0.0001) (Rodrigues et 
al., 2013). The insertion/deletion variant, located at the 
5´of the APOB, was associated with greater reduction 
of plasma LDL cholesterol after long term treatment 
with fluvastatin (4 months), however c.7545C>T and 
c.12451G>A (EcoRI) did not influence the response to 
fluvastatin (Guzman et al., 2000) or short term treatment 
with atorvastatin (Rodrigues et al., 2013). 
Proprotein convertase subtilisin/kexin type 9 
(PCSK9) is an enzyme that degrades the LDL receptor, and 
contributes to the cholesterol intracellular homeostasis. 
Functional polymorphisms (gain in function) in PCSK9 
have been associated with a lower response to statins 
(Gelissen, McLachlan, 2014; Gryn, Hegele, 2014; 
Alfonsi, Hegele, Gryn, 2016). Whereas non-functional 
(loss of function) variants were related to increased statin 
response, which was the basis of the development of the 
PCSK9 inhibitors (Burke et al., 2017).
Four var iants  of  the PCSK9 (c .2009A>G, 
c.1420A>G, c.137G>T and c.*614T>C) were analyzed 
in Brazilian HC subjects, but no one was associated 
with response to short term treatment with atorvastatin 
(Anderson et al . ,  2014; Zambrano et al . ,  2015). 
Interestingly, carriers of the c.2009G allele had higher 
basal plasma LDL cholesterol (Anderson et al., 2014).
The myosin regulatory light chain-interacting 
protein (MYLIP), also named E3-ubiquitin ligase, is a 
cytoskeletal effector protein that links actin to membrane-
bound proteins at the cell surface. MYLIP causes the 
ubiquitination of the LDL receptor cytoplasmic domain, 
thereby promoting its degradation and rising plasma 
LDL cholesterol. Polymorphisms in MYLIP have been 
associated with variability in plasma cholesterol and 
response to statins (Gelissen, McLachlan, 2014).
Santos et al. investigated the influence of MYLIP 
c.1025G>A variant on plasma lipids in heterozygous 
FH patients. They showed that AA genotype was 
associated with better response to long term treatment 
with atorvastatin and ezetimibe, a cholesterol absorption 
inhibitor, in subjects carrying LDLR mutations (Santos et 
al., 2014a).
Cholesterol homeostasis-related genes
Sterol regulatory element-binding factors (SREBFs) 
and SREBF cleavage-activating protein (SCAP) are 
important regulators of the cholesterol homeostasis, 
mostly by activating hepatic synthesis of fatty acids 
and cholesterol. SREBFs are activated by low level of 
intracellular cholesterol, in a sequence of steps including 
the SCAP-mediated transfer from endoplasmic reticulum 
to the Golgi. Activated SREPFs are transferred to nucleus 
to induce the transcription of the cholesterogenic genes, 
such as HMGCR and LDLR that results in normalization 
of the intracellular cholesterol level. Polymorphisms in 
the SREBF1, SREBF1 and SCAP encoding genes have 
been implicated in the variability of plasma lipids and in 
the response to lipid-lowering drug (Gryn, Hegele, 2014).
The influence of the SRBEF1 ,  SREBF2  and 
SCAP polymorphisms on lipid-lowering response to 
statins were evaluated in two studies with Brazilian HC 
subjects. SRBEF1 c.-36del>G and SREBF2 c.1784G>C 
variants were not associated with plasma lipids response 
to simvastatin (Fiegenbaum et al., 2005c). We also did 
not find relationship between SRBEF1 c.-36del>G and 
the atorvastatin cholesterol-lowering response (Arazi 
et al., 2008). HC subjects carrying the G allele of the 
SCAP 2386A>G polymorphism had high plasma total 
cholesterol and increased response of total cholesterol 
and triglycerides to simvastatin treatment for six months 
(Fiegenbaum et al., 2005c). Our research group reported 
that SCAP 2386GG genotype carriers had reduction of 
SCAP mRNA expression in PBMC, but the polymorphism 
did not influence the lipid response to atorvastatin (Arazi 
et al., 2008).
Lipid metabolism-related genes
Apolipoprotein E (ApoE) has an important role 
in the liver uptake of the triglyceride-rich lipoproteins, 
such as VLDL and its remnant, via LDL and lipoprotein 
receptor-related protein (LRP) receptors. The gene 
encoding the ApoE (APOE) has three main alleles (ε2, 
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ε3, and ε4), which encodes ApoE isoforms with different 
affinities for cell surface receptors. Candidate genes and 
genome-wide association studies have suggested that 
APOE polymorphism is as a robust marker of statin-
induced cholesterol lowering response, but there is not 
a clear association with cardiovascular events (Gelissen, 
McLachlan, 2014; Gryn, Hegele, 2014; Patel et al., 2014; 
Postmus et al., 2014; Leusink et al., 2016; Ruaño et al., 
2016).
Four studies evaluated of APOE polymorphism in 
Brazilian HC patients treated with statins. APOE alleles 
did not influence plasma lipids after long term treatment 
with simvastatin (Fiegenbaum et al., 2005b) and short 
term treatment with atorvastatin (Cerda et al., 2011b). We 
also reported no association between APOE genotypes and 
lipid-lowering response to atorvastatin combined or not with 
hormonal therapy for three months in postmenopausal HC 
women (Issa et al., 2012). As reported by previous studies, 
we found an association of APOE *2 allele with lower risk 
for hypercholesterolemia (OR: 0.27, CI95%; 0.01-0.85, 
p=0.025) (Cerda et al., 2011b). Interestingly, APOE *3*3 
genotype carriers had greater reduction of APOE mRNA 
levels in PBMC after atorvastatin treatment (Issa et al., 
2012). Another study investigated the APOE g.4798T>G 
in subjects with statin-controlled dyslipidemia and did not 
find association with oxidative stress biomarkers and plasma 
tocopherol (Botelho et al., 2012).
Hepatic lipase, encoded by LIPC, has an important 
role in lipid metabolism by hydrolyzing triglycerides and 
phospholipids in plasma lipoproteins and by acting as a 
bridging factor for receptor-mediated lipoprotein uptake. 
Variants of LIPC have been associated with response to 
statins (Leusink et al., 2016).
Two studies investigated the influence of LIPC 
polymorphisms in Brazilian HC patients treated with 
statins. Fiegenbaum et al reported lack of association 
between LIPC -250G>A and variability in plasma lipids 
after long term treatment with simvastatin (Fiegenbaum 
et al., 2005b). Whereas, our group described that C allele 
carriers of the LIPC -514C>T are more likely to have 
better response to atorvastatin (OR: 0.27, CI95%: 0.08-
0.90, p=0.003) (Rodrigues et al., 2013). 
Reverse cholesterol transport-related genes
ABCA1 and ABCG1 are membrane transporters 
involved in the cholesterol efflux from cells to lipid poor 
apolipoprotein A-I (ApoA-I) in nascent discoidal HDL. 
In this way ABCA1and ABCG1 transporters and ApoA-I 
as well play important roles in the biogenesis of HDL 
and the reverse transport of cholesterol from the cells to 
the liver. Polymorphisms in the gene cluster encoding 
apolipoproteins A1-C3-A4-A5-BUD13 were reported 
to affect triglycerides and LDL cholesterol responses to 
statins (Gryn, Hegele, 2014). 
Our group investigated the influence of three ABCA1 
polymorphisms (c.-327C>T, c.-418C>T and c.656G>A) 
and two APOA1 variants (-75G>A and 83C>T) on 
short term atorvastatin treatment. Carriers of ABCA1 
c.-418T and c.656A alleles had high basal serum HDL 
cholesterol and low triglycerides and VLDL cholesterol, 
but ABCA1 variants were not associated of with response 
to atorvastatin (Genvigir et al., 2008). APOA1 -75A allele 
was associated with high basal serum triglycerides and 
VLDL cholesterol in HC men, and APOA1 -75GG/83CC 
haplotype was associated with higher reduction of 
triglycerides and VLDL cholesterol after atorvastatin 
treatment in HC women (Sorkin et al., 2005).
Cholesteryl ester transfer protein (CETP) mediates 
the exchange of cholesteryl ester for triglycerides between 
HDL and the apoB-containing lipoproteins VLDL and 
LDL. Polymorphisms in CETP have been associated with 
variability in HDL cholesterol levels and cardiovascular 
events in patients treated with statins (Patel et al., 2014; 
Alfonsi, Hegele, Gryn, 2016; Leusink et al., 2016; Ruaño 
et al., 2016).
The influence of the CETP Taq1B (g.5454G>A) 
polymorphism in HC treated with statins was reported in 
two Brazilian studies. CETP B2B2 genotype was shown to 
increase the HDL cholesterol after long term of simvastatin 
treatment (Fiegenbaum et al., 2005b). Whereas CETP 
Taq1B variant was not associated with differences in 
plasma tocopherol and oxidative stress biomarkers, such 
as malondialdehyde, oxidized LDL and total antioxidant 
activity, in a study with HC subjects treated with 
simvastatin or atorvastatin (Botelho et al., 2012). 
The scavenger receptor BI (SR-BI) has also an 
important role in the final step of the reverse cholesterol 
transport, by mediating the liver uptake of the HDL-
associated cholesterol esters, which are excreted through 
the bile. Several polymorphisms in genes involved in 
the cholesterol lowering pathway were investigated for 
modification of the effectiveness of statins in reducing 
the risk for myocardial infarction. SCARB1 variants had 
the most significant interaction with statin effectiveness 
(Peters et al., 2011).
Three polymorphisms (c.4G>A, c.726+54C>T, 
c.1050C>T) in the SCARB1, which encodes the SR-
BI, were investigated by our group, in HC subjects 
treated with atorvastatin during 4 weeks. Carriers of 
SCARB1 c.1050C allele had less reduction of total 
cholesterol, LDL cholesterol and apoB plasma levels in 
response to atorvastatin (Cerda et al., 2010). SCARB1 
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c.726+54T allele was associated with high basal plasma 
LDL cholesterol and apoB, and low SCARB1 mRNA 
expression in PBMC before and after atorvastatin 
treatment (Cerda et al., 2011a). SCARB1 variants were 
not associated with plasma lipids or SCARB1 mRNA 
expression in PBMC of HC subjects after treatment with 
ezetimibe (10 mg/day/4weeks) and simvastatin (10mg/
day/8weeks) monotherapies and combined therapy 
(ezetimibe+simvastatin: 10mg/day/4weeks) (Cerda et 
al., 2011a).
Cluster determinant 36 (CD36), also named fatty 
acid translocase (FAT), is a membrane glycoprotein 
with various cellular functions, including oxidized LDL 
receptor (scavenger receptor type B), mechanisms of 
angiogenesis and gustatory perception of fatty acids. 
Using a candidate gene approach, we investigated the 
effects of polymorphisms in CD36 and other genes related 
to lipid metabolism and atherosclerosis in a sample of 
Brazilian population. CD36 g.16417A>G was associated 
with hypercholesterolemia (OR: 3.7, CI95%: 1.9-7.0, 
p=0.0002), but not with response to short term treatment 
with atorvastatin (Rodrigues et al., 2013).
Paraoxonase 1 (PON1) is an enzyme with important 
roles in the detoxification of the oxidized LDL and 
prevention of the HDL lipid peroxidation. PON1 has been 
suggested to be a cardioprotective agent in atherosclerosis 
and related vascular diseases (Cerda, Hirata, Hirata, 
2012). The polymorphisms c.575A>G (Gln192Arg) 
and c.163T>A (Leu55Met) in the PON1 were studied 
in a sample of Brazilian HC subjects. Carriers of PON1 
192Arg and 55Met alleles are more likely of achieving 
HDL cholesterol goals after long term treatment with 
simvastatin and atorvastatin (OR: 2.81, CI95%:1.35-5.85, 
P =0.006) (De Souza et al., 2015). On the other hand PON1 
Gln192Arg was not associated with differences in plasma 
tocopherol and oxidative stress biomarkers, in HC subjects 
treated with simvastatin or atorvastatin for six months 
(Botelho et al., 2012). 
Estrogen receptor alpha, encoded by ESR1, is a 
ligand-activated transcription factor involved in the 
signaling of the estrogen physiological effects in the 
female body, including the regulation of genes involved 
in the metabolism of HDL and other lipoproteins. Two 
variants in the ESR1 (g.190510T>C and g.448305T>C) 
were studied in a large sample of HC Brazilian subjects. 
g.448305T>C was associated with greater reduction 
of plasma total cholesterol and LDL cholesterol after 
treatment with simvastatin and atorvastatin for six 
months, in HC women. Moreover, carriers of g.190510CC 
genotype showed increased HDL cholesterol in response 
to statins (Smiderle et al., 2016).
Endothelial function-related genes
M e t h y l e n e t e t r a h y d r o f o l a t e  r e d u c t a s e 
(MTHFR) is involved in the methyl cycle generating 
5-methylhydrofolate used for conversion of homocysteine 
to methionine. Endothelial dysfunction can be caused 
by hyperhomocysteinemia, which has been considered 
an independent risk factor for cardiovascular diseases. 
Polymorphisms in MTHFR and other genes were suggested 
to be predictors for slow atorvastatin metabolism (León-
Cachón et al., 2016). A Brazilian study reported the 
association of MTHFR c.677C>T polymorphism with 
homocysteine reduction and nitrite in plasma after 
simvastatin treatment, in obese women (Villela et al., 
2014).
The endothelial nitric oxide synthase (eNOS) 
produces the vasodilator nitric oxide (NO), which 
regulates the vascular system by inhibition of platelet 
aggregation, leukocyte adhesion and smooth muscle 
proliferation. Variants in the eNOS encoding gene (NOS3) 
have been associated with myotoxicity of statins (Gryn, 
Hegele, 2014; Ruaño et al., 2016).
Three studies investigated the NOS3 -786T>C 
polymorphism was studied in Brazilian subjects. This 
variant was not associated with short term treatment with 
short term treatment with atorvastatin in health men, but 
blood nitrite was increased and plasma malondialdehyde 
was reduced in carriers of the NOS3 -786CC genotype 
(Nagasaki et al., 2006). The CC genotype was also 
associated with reduction of plasma sCD40-L, sVCAM, 
sP-selectin and MMP-9 in response to atorvastatin, in 
health men (Souza-Costa et al., 2007). NOS3 -786C allele 
was also associated with the increase in blood nitrite but 
not with the reduction of plasma malondialdehyde in obese 
women treated with simvastatin (Andrade et al., 2013).
Manganese-dependent superoxide dismutase 
(SOD2) is an antioxidant enzyme that prevents the 
deleterious effects of the superoxide anion, a reactive 
oxygen specie that is involved in the pathophysiology 
of atherosclerosis and other vascular diseases. The 
influence of SOD2 Val16Ala (c.47T>C) on plasma lipids 
was evaluated in Brazilian HC patients. The VV (TT) 
genotype carriers had less intense reduction of plasma 
total and LDL cholesterol, anti-inflammatory and anti-
fibrinolytic markers in response to long term treatment 
with rosuvastatin (Duarte et al., 2016).
PHARMACOGENETICS AND DIABETES 
The increasing prevalence of obesity worldwide in 
the last decades have become this disease one of the most 
important public health problems nowadays, positioning to 
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obesity-related metabolic diseases and CVD as one of the 
main causes of death in developed as well as developing 
countries (Bastien et al., 2014). 
In this way, T2D has been considered a major health 
problem, affecting more than 415 million people. Several 
classes of antidiabetic drugs are currently prescribed, 
including mainly biguadines, sulfonylureas, meglitidines 
and thiazolidinediones (Chamberlain et al., 2017). The 
treatment strategy is mostly based on efficacy of oral 
antidiabetic drugs assessed by the level of fasting or 
postprandial glycaemia and/or glycated hemoglobin 
(HbA1c). Pharmacogenetic studies have proposed several 
genes involved in the response to antidiabetic drugs 
(Singh, Usman, Banerjee, 2016).
Curiously, in Brazilian population the influence of 
genetic variants in genes participating in pharmacokinetics/
pharmacodynamics of oral antidiabetic drugs are almost 
inexistent. We identified only one study from our research 
group that evaluated the role of polymorphisms in the 
genes encoding the tumor necrosis factor alpha (TNF) 
and interleukin 6 (IL6) in 53 T2D patients treated with 
pioglitazone, an antidiabetic drug that enhances the 
expression of the peroxisome proliferator-activated 
receptor-gamma (PPARγ), leading to improved sensitivity 
to insulin but that also can induce bone loss. TNF -308G>A 
(g.4682G>A, rs1800629) and IL6 -174G>C (c.-237C>G, 
rs1800795) polymorphisms were not associated with 
pioglitazone response regarding glycemic control, 
however the TNF -308A allele carriers had lower values 
of total alkaline phosphatase (tALP) in T2D patients after 
pioglitazone treatment (Himelfarb et al., 2011). 
Regarding the treatment of obesity, in the last years 
Brazilian studies have mainly focused in the evaluation 
of the role of genetic variation on the response to surgical 
treatment of obesity (Nicoletti et al., 2017); however, the 
influence of genetic polymorphisms on pharmacological 
strategies for weight loss have not been evaluated until 
now.
Evaluating the pharmacogenetic implications of 
antidiabetic and antiobesity drugs in Brazilian populations 
is challenge due to the scarce information in the scientific 
literature. Further studies are necessary in order to 
elucidate the contribution of genetic background of our 
population to the pharmacological response regarding 
the treatment of the most prevalent diseases related to 
cardiovascular risk. 
PHARMACOGENETICS AND HYPERTENSION 
Hypertension is a very important public health 
issue, because it affects about one billion adult globally 
and is the most important risk factor to causa mortis in the 
contemporary society: coronary artery diseases, stroke, 
renal dysfunction and heart failure (Savoia et al., 2017).
A small subset of the hypertensive population is 
affected by monogenic disease; however the majority of 
cases of hypertension are multifactorial and polygenic. 
There is a complex trait of etiology involving an intricate 
network between homeostasis of extracellular body 
fluid, vascular tone regulated by renal system, cardiac 
contractility, neuroendocrine system and others factors 
such as age, weight, ethnicity, lifestyle and diet (Savoia 
et al., 2017). 
Currently, the most commonly used antihypertensives 
are: (i) angiotensin I-converting enzyme (ACE) inhibitors, 
such as enalapril; (ii) angiotensin II-receptor blockers 
(ARBs), such as losartan; (iii) β-blockers, for example, 
atenolol; (iv) calcium-channel blockers, such as 
nifedipine; and (v) diuretics, such as spironolactone or 
hydrochlorothiazide. Even though these antihypertensive 
drugs are effective and well tolerated, only about half of 
patients with treated hypertension achieve appropriate BP 
control (Savoia et al., 2017). This variability is caused 
by genetic and non-genetic factors, which are known 
can cause primary and secondary hypertension (Cooper-
DeHoff, Johnson, 2016).
The pharmacogenetic approaches in Brazilian 
population have involved primary (majority) hypertensive 
patients (HP), resistant hypertensive patients (RHP), 
gestational hypertensive (GHP) and preeclamptic patients 
(PP). The studies including GHP and PP were recently 
and very well reviewed by Luizon et al. (2017). The main 
results of the pharmacogenetic studies with HP and RHP 
are described in this review.
HP have been defined as systolic BP (SBP) ≥140 
mmHg and diastolic BP (DBP) ≥90 mmHg, with BP 
measurement obtained from the average of three BP 
readings on at least two office visits with the individuals 
in the seated position. RHP have been defined according to 
the Statement of American Heart Association as all subjects 
with BP that remains above goal in spite of the concurrent 
use of 3 antihypertensive agents of different classes 
(ideally among them, a diuretic) in optimal doses. Also the 
definition includes patients whose BP is controlled using 
four or more antihypertensive medications (Malachias 
et al., 2016). By the way, the use of multiple drugs is an 
inherent limitation of the pharmacogenetic studies with 
RHP. The mechanisms of resistance to antihypertensive 
treatment are not fully elucidated, but have been associated 
to excess sodium and fluid retention, increased activation 
of the renin-angiotensin-aldosterone system (RAAS), 
heightened activity of the sympathetic nervous system, 
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endothelial dysfunction, arterial stiffness, left ventricular 
hypertrophy, microalbuminuria and deregulation of 
inflammatory adipokines (Hwang et al., 2017). 
The pharmacogenetic studies of antihypertensive 
drugs in samples of the Brazilian population are listed in 
the Table III.
Pharmacokinetics-related genes
Two Brazilian studies investigated the influence 
of polymorphisms in genes encoding drug metabolizing 
and transporters on response to antihypertensive therapy, 
including hydralazine.
Hydralazine is a vasodilator metabolized by an 
acetylation reaction mediated by N-acetyltransferase 2 
(NAT2), a drug metabolizing enzyme. Several alleles of 
the NAT2, which encodes NAT2 enzyme, are associated 
with slow acetylation phenotypes (191A, 341C, 590A, 
857A). Spinasse et al investigated 15 different NAT2 
polymorphisms, including two new variants (30T>A and 
824T>C), in Brazilian RHP prescribed with a therapeutic 
scheme containing hydralazine. In a subset of 61 patients, 
significant BP reductions were observed in the carriers 
of slow acetylator alleles. Four of RHP patients had 
hydralazine-induced adverse effects, and three of them 
were slow NAT2 acelylators (Spinasse et al., 2014).
The influence of ABCB1 polymorphisms on 
antihypertensive response was also investigated in 
Brazilian subjects. ABCB1 c.3435C>T (rs1045642) 
was not associated with resistance to antihypertensive 
treatment. Interestingly, in RHP, c.3435CC genotype was 
associated with higher BP (Lacchini et al., 2014). 
Pharmacodynamics-related genes
The components of the RAAS pathway, such as 
ACE, angiotensinogen, angiotensin II receptor type 1 (AT1 
receptor) and aldosterone, play an important role in BP 
control. The polymorphisms in the genes encoding RAAS 
proteins and other pharmacodynamics-related genes can 
influence the response to antihypertensive drugs. Results 
from pharmacogenetic studies in Brazilian HP are shown 
in Table III.
A C E  h a s  a  2 8 7  b p  i n s e r t i o n / d e l e t i o n 
(g.16457_16458insG, Indel, rs1799752) polymorphism 
in intron 16 that is the most well-known variant. The 
ACE del variant has been associated with increased 
plasma levels of ACE, which potentially increases the BP 
(Thorn et al., 2010). Previous studies have analyzed the 
influence of the variant on the pharmacological response 
with contradictory results (Thorn et al., 2010). In Brazilian 
older women, no association was found between the ACE 
Indel and the amplitude of the reduction of BP in response 
to antihypertensive drugs (Moraes et al., 2008). Likewise, 
ACE rs1799752 was not a genetic risk factor for resistant 
hypertension (Yugar-Toledo et al., 2011). 
Polymorphisms in the AGT, which encodes the 
angiotensinogen, such as the Met268Thr (rs699), have 
not been associated with differences in BP reduction after 
treatment with ACE inhibitors or ARBs (Konoshita et al., 
2011). Interestingly, in individuals from Brazil treated 
with combinations of antihypertensive drugs (which is 
the case in RHP), there was an association between AGT 
Met268Thr polymorphism and increased risk for resistant 
hypertension. The 268Thr carriers presented an increased 
risk, especially if they were older than 50 years (Yugar-
Toledo et al., 2011).
Polymorphisms in the gene encoding AT1 receptor 
(AGTR1) have been shown to be associated with 
differences in response to antihypertensive drugs (Fontana, 
Luizon, Sandrim, 2015). The AGTR1 c.*86A>C (rs5186) 
variant, that is located in the 3´UTR and may affect gene 
transcription, was studied in a sample of Brazilian older 
women, but no association was found with BP reduction. 
Bradykinin is a potent vasoactive peptide that 
induces vasodilation, releases of NO and promotes water 
and sodium excretion, which are mediated by bradykinin 
receptors (BDKRs). Variants in the gene encoding BDKR 
type B2 (BDKRB2) were associated with the risk of 
hypertension (Luo, Kang, Xu, 2015). Two polymorphisms 
in BDKRB2, c.-192C>T (-58C>T) and Indel exon 1 
(BE1 +9/-9), have been studied in Brazilian hypertensive 
patients. BDKRB2 -58TT genotype was associated with 
poor response to enalapril, an ACE inhibitor. Moreover, 
-58CC genotype was associated with better response 
depending on presence of NOS3 -786TC genotype (Silva 
et al., 2013). On the other hand, no association was found 
between BDKRB2, -58C>T and the response to enalapril 
in another sample of Brazilian HP subjects (Oliveira-Paula 
et al., 2017). The Indel BE1 9-bp repeat sequence was 
also not associated with the response to antihypertensive 
therapy in HP subjects (Silva et al., 2013; Oliveira-Paula 
et al., 2017).
Aldosterone synthase is a member of the cytochrome 
P450 family responsible for the final step of aldosterone 
synthesis in the adrenal cortex. The gene encoding 
aldosterone synthase, CYP11B2, is the hot spot for 
essential hypertension susceptibility genes (Chen et 
al., 2015). The results of association studies between 
the CYP11B2 c.-344C>T (rs1799998) polymorphism 
and essential hypertension, or aldosterone levels, are 
controversial. In Brazilian individuals, this SNP was not 
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associated with resistant hypertension (Lacchini et al., 
2009); nevertheless the c.-344TT genotype and use of 
spironolactone were independent predictors of aldosterone 
levels in RHP (Fontana et al., 2014).
The inducible oxide nitric synthase (iNOS, NOS2) 
is calcium-independent and generates more NO than 
the constitutive members, neuronal (nNOS, NOS1) and 
endothelial (eNOS, NOS3) isoforms. The regulation 
of NOS2 expression is stimulated by multiple factors 
including inflammatory cytokines and stress signals 
(Sorokin, 2016). Three variants in NOS2, the microsatellite 
(CCTTT)n, g.-1026C>A (rs2779249) and g.2087G>A 
(rs2297518), were investigated in Brazilian individuals. 
The results showed that (CCTT)n<12CA haplotype was 
associated with lower risk of resistant hypertension 
(responsiveness to antihypertensive therapy) (Oliveira-
Paula et al., 2013).
NOS3, constitutively expressed in vascular 
endothelium, is the most important isoform for NO formation 
in the cardiovascular system (Sorokin, 2016). NOS3 
variants have been the most studied in pharmacogenetic 
approaches with Brazilian hypertensive patients. The 
-786T>C (rs2070744) polymorphism was not associated 
with resistance to antihypertensive therapy (Sandrim et 
al., 2006), but it seems to be related to a better therapeutic 
response to enalapril (Silva et al., 2013; Oliveira-Paula 
et al., 2017). Likewise, the NOS3 rs3918226T allele and 
TCA haplotype of the tagSNPs (rs3918188, rs3918226 and 
rs743506) were associated with better response, whereas 
the rs3918188A allele and CAG haplotype were associated 
with worse antihypertensive response to enalapril 10 and/
or 20mg/day (Oliveira-Paula et al., 2016). The NOS3 
Asp298Glu (rs1799983) and 4b/4a VNTR polymorphisms 
were not associated with responsiveness to therapy (Silva et 
al., 2013; Oliveira-Paula et al., 2017) or with resistance to 
treatment (Sandrim et al., 2006; Yugar-Toledo et al., 2011) 
in Brazilian individuals. 
The mineralocorticoid receptor (MR) or nuclear 
receptor subfamily 3, group c, member 2 (NR3C2) 
belongs to the nuclear receptor superfamily and functions 
as a ligand-dependent transcription factor that mediates 
the effects of aldosterone on a variety of target tissues. 
Variants in NR3C2, which encodes MR, affected BP 
response to enalapril treatment in Chinese hypertensive 
patients (Luo et al., 2014). In Brazilian individuals, 
the NR3C2  Val180Ile  and c.-2G>C (rs2070951) 
polymorphisms were not associated with resistance 
to antihypertensive therapy. Interestingly, in RHP, 
increased levels of aldosterone and more prevalent left 
ventricular hypertrophy were associated with Val180Ile 
polymorphism. 180Val/c.-2G haplotype also was 
associated with higher plasma aldosterone in RHP (Ritter 
et al., 2016).
Protein kinase C (PKC) signaling is involved 
in the vascular control mechanisms of BP. A genome 
wide association study (GWAS) revealed an intronic 
SNP, g.494902G>A (rs16960228), in gene encoding 
of the isoform PKC alpha (PRKCA) as an important 
predictor of hydrochlorothiazide and atenolol response. 
The rs16960228 A allele carriers had a greater 
hydrochlorothiazide BP response compared to GG 
carriers; however, an opposite direction of effect was 
found in participants treated with a β-blocker, atenolol 
(Cooper-DeHoff, Johnson, 2016). Three variants in 
PRKCA (rs887797, rs1010544 and rs16960228) were 
investigated in 104 Brazilian HP. PRKCA g.393521 
(rs1010544) C allele was associated with better response 
to enalapril therapy, whereas the rs16960228 A allele 
and CTA haplotype had the opposite effect. Moreover, 
the rs16960228 GG genotype combined with BDKRB2 
-58CC (rs1799722) and NOS3 -786TC or TT (rs2070744) 
genotypes were associated with good or poor response to 
treatment, respectively (Oliveira-Paula et al., 2017).
Vascular endothelial growth factor (VEGF) 
has many biological roles, including migration and 
proliferation of endothelial cells and increase of vascular 
permeability. VEGF by stimulating NOS expression 
and NO activity also has a significant role in BP control 
(Mazidi et al., 2017). Because ACE inhibitors seem 
to up-regulate VEGF expression, Oliveira-Paula et al. 
(2015) investigated the influence of three VEGFA variants 
in Brazilian HP treated with enalapril. The authors 
found that after treatment with enalapril 20 mg/day, the 
-2578C>A (rs699947) polymorphism predisposed to better 
antihypertensive response. Moreover, the haplotype AGG 
(-2578C>A, c.-1154G>A and c.-634G>C polymorphisms) 
was associated with more intense decrease in BP, while 
the opposite was found to be associated with the CGG 
haplotype. Conversely, these VEGFA polymorphisms 
were not associated with resistance to antihypertensive 
treatment in another sample of the Brazilian population 
(Sandrim et al., 2013).
Other genes 
Polymorphisms in genes encoding adipokines, such 
as leptin (LEP), leptin receptor (LEPR) and adiponectin 
(ADIPOQ), have been also studied in Brazilian sample 
population due to the relationship of alterations in 
these proteins with hypertension (Table III). ADIPOQ 
(-11377C>G and 276G>T), LEP (-2548G>A) and LEPR 
(c.668A>G) were not associated with the response 
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Braz. J. Pharm. Sci. 2018;54(Special):e0100520
to antihypertensive therapy in RHP (de Faria et al., 
2015; de Faria et al., 2017). Interestingly, carriers of 
ADIPOQ -11377G and 276T alleles had lower and higher 
adiponectin concentrations, respectively (de Faria et al., 
2015). Moreover, RHP carrying the LEP -2548AA or 
LEPR c.668AA genotypes, compared to GG, presented a 
worse metabolic profile (de Faria et al., 2017).
Matrix metalloproteinases (MMPs) comprise a 
family of zinc and calcium-dependent proteases that 
degrade different components of the extracellular 
matrix, both in physiological and in pathophysiological 
conditions (Pulkoski-Gross, 2015). Previous review 
has showed the importance of MMP-2 in hypertension 
(Belo, Guimarães, Castro, 2015). The association of the 
three SNPs located in the promoter region of MMP2 
(-1575G>A, -1306C>T and -735C>T), with resistant 
hypertension was evaluated in Brazilian individuals 
(Table III). The -735C allele and GCC haplotype carriers 
showed increased risk to resistant hypertension, whereas 
the GCT haplotype had an opposite effect (Sabbatini et 
al., 2017). 
CONCLUSIONS AND FUTURE PERSPECTIVES
Metabolic disorders represent an important group of 
pathologies and risk factors related to the development of 
CVD and the pharmacological and non-pharmacological 
management of these conditions are closely related to the 
high rates of morbidity and mortality by non-communicable 
diseases in our population. Genetic admixture of Brazilian 
populations is a challenge for genetic approaches to study 
complex disorders and multifactorial events, including 
pharmacogenetics, and frequently the data from well-
defined ethnic groups are not applicable to Brazilian 
populations.
Pharmacogenetic studies of metabolic diseases 
in Brazilian population have explored a number of 
cardiovascular drugs for the treatment of dyslipidemia 
and hypertension; however, evaluating the role of 
genetic variability in response to antidiabetic drugs and 
pharmacological management of weight loss is still a 
challenge in this population. Considering that obesity and 
insulin resistance/T2D are the most prevalent diseases 
related to cardiovascular risk in developing countries, 
further pharmacogenetic studies are necessary in order to 
elucidate the contribution of genetic background of our 
population for effectiveness and safety of these drugs. 
Pharmacogenetic studies of dyslipidemia have 
evaluated almost exclusively the response to statins, 
being necessary to expand the scope of pharmacogenetics 
to other lipid-lowering drugs. In the same line, it is also 
important to spread out the repertory of gene variants 
implicated in pharmacological response of cholesterol-
lowering drugs to new mechanism of drug actions, mainly 
due to the broad applications of statin-induced pleiotropic 
effects. 
Regarding pharmacogenetic studies of anti-
hypertensive drugs, here the influence of genetic variants 
on HP and HRP in Brazilian populations was reviewed. 
Genetic causes of inadequate response to antihypertensive 
therapy are of great importance, mainly by the fact that 
a small proportion of these individuals achieve BP levels 
according to recommendations. Results from Brazilian 
studies demonstrated that response to antihypertensive 
drugs could be affected by the variability of diverse 
genes, including genes implicated in pharmacokinetics/ 
pharmacodynamics as also genes that not necessarily 
are directly involved in drug action. These studies have 
shown limitations in number and sample size, which make 
difficult to establish strong conclusions about their impact 
in our population. 
In conclusion, although several pharmacogenetic 
studies evaluating drug response of metabolic diseases 
have been performed in Brazilian populations, a small 
sample size has been a constant in these studies, which 
limits the conclusions and clinical applications in our 
populations.
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